(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are ADOCIA, GYLDENDAL, and TEIXEIRA DUARTE.

Financial Asset	Price	Change	Updated (EST)
ADOCIA (ADOC.PA)	5.86	11.62%	2024-07-16 12:45:09
GYLDENDAL (GYL.OL)	500.00	11.11%	2024-07-16 12:40:21
TEIXEIRA DUARTE (TDSA.LS)	0.12	10.58%	2024-07-16 12:24:01
MAGNORA (MGN.OL)	30.40	5.72%	2024-07-16 12:41:06
HOFSETH BIOCARE (HBC.OL)	2.17	4.83%	2024-07-16 12:40:28
JINHUI SHIPP TRANS (JIN.OL)	6.70	4.69%	2024-07-16 12:40:41
NAPATECH (NAPA.OL)	34.50	3.29%	2024-07-16 12:41:18
NRC GROUP (NRC.OL)	10.55	2.93%	2024-07-16 12:41:44
VALUE8 CUM PREF (PREVA.AS)	4.81	2.88%	2024-07-16 12:04:39
BELSHIPS (BELCO.OL)	23.30	2.87%	2024-07-16 12:25:04

The three biggest losers today are ATOS, BENEVOLENTAI, and PHOTOCURE.

Financial Asset	Price	Change	Updated (EST)
ATOS (ATO.PA)	1.14	-10.8%	2024-07-16 12:46:09
BENEVOLENTAI (BAI.AS)	0.61	-10.56%	2024-07-16 12:00:56
PHOTOCURE (PHO.OL)	53.20	-9.22%	2024-07-16 12:42:21
MOTORK (MTRK.AS)	5.50	-7.72%	2024-07-16 12:03:06
ALFEN (ALFEN.AS)	17.48	-5.41%	2024-07-16 12:00:21
ATLANTIC SAPPHIRE (ASA.OL)	5.30	-5.12%	2024-07-16 12:24:49
GLINTT (GLINT.LS)	0.48	-5.1%	2024-07-16 12:23:21
CELYAD ONCOLOGY (CYAD.BR)	0.26	-4.94%	2024-07-16 12:05:50
COFINA,SGPS (CFN.LS)	0.82	-4.88%	2024-07-16 12:23:05
SEQUANA MEDICAL (SEQUA.BR)	1.21	-4.35%	2024-07-16 12:21:23

Winners today

1. ADOCIA (ADOC.PA)

11.62% Price Change

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-term delivery of therapeutic agents. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

CAC 40 ended the session with ADOCIA rising 11.62% to €5.86 on Tuesday, after four consecutive sessions in a row of losses. CAC 40 slid 0.69% to €7,580.03, after three consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, ADOCIA has a trailing twelve months EPS of €-1.9.

Moving Average

ADOCIA’s worth is way below its 50-day moving average of €9.07 and way below its 200-day moving average of €6.63.

Revenue Growth

Year-on-year quarterly revenue growth declined by 62.6%, now sitting on 10.84M for the twelve trailing months.

Yearly Top and Bottom Value

ADOCIA’s stock is valued at €5.86 at 22:40 EST, way under its 52-week high of €16.16 and way higher than its 52-week low of €2.74.

Volatility

ADOCIA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 8.54%, a negative 1.81%, and a positive 3.55%.

ADOCIA’s highest amplitude of average volatility was 8.54% (last week), 6.27% (last month), and 3.55% (last quarter).

More news about ADOCIA.

2. GYLDENDAL (GYL.OL)

11.11% Price Change

Gyldendal ASA, through its subsidiaries, publishes and sells books in Norway. It also develops, produces, and publishes content, including learning materials for kindergarten, primary school, upper secondary school, students, and other professional market; and sells paper books, e-books, audiobooks, and digital books, and other goods, as well as provides streaming services. The company operates through physical bookstores and online bookstore. Gyldendal ASA was founded in 1925 and is headquartered in Oslo, Norway. Gyldendal ASA operates as a subsidiary of Erik Must AS.

Oslo Børs Benchmark Index_GI ended the session with GYLDENDAL rising 11.11% to €500.00 on Tuesday while Oslo Børs Benchmark Index_GI slid 0.15% to €1,425.29.

Earnings Per Share

As for profitability, GYLDENDAL has a trailing twelve months EPS of kr-16.65.

Volatility

GYLDENDAL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 8.44%, a negative 1.18%, and a positive 5.18%.

GYLDENDAL’s highest amplitude of average volatility was 8.44% (last week), 7.27% (last month), and 5.18% (last quarter).

Volume

Today’s last reported volume for GYLDENDAL is 50 which is 1150% above its average volume of 4.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GYLDENDAL’s stock is considered to be overbought (>=80).

More news about GYLDENDAL.

3. TEIXEIRA DUARTE (TDSA.LS)

10.58% Price Change

Teixeira Duarte, S.A. operates in the construction, concessions and services, real estate, hospitality, distribution, and automotive sectors in Portugal and internationally. The company is involved in the various construction activities, including geotechnical engineering and rehabilitation, buildings, infrastructures, and metalworking, as well as underground, railway, and maritime works; and the provision of concessions and services in various business areas, such as facilities management, facilities services, environment, and education. It also develops real estate properties; and operates hotels in Angola, Mozambique and Portugal. In addition, the company distributes food products through MAXI grocery stores; operates restaurants under the Pastelarias Nilo name; offers pharmacy products through Farmácia Popular stores; provides furniture and decoration products under the Dakaza brand; and distributes and integrates FMCG brands. Further, it sells light and heavy-duty cars, motorcycles, and equipment; and provides technical assistance. Teixeira Duarte, S.A. was founded in 1921 and is headquartered in Oeiras, Portugal.

PSI ended the session with TEIXEIRA DUARTE rising 10.58% to €0.12 on Tuesday, after two successive sessions in a row of gains. PSI jumped 1.04% to €6,775.93, after three sequential sessions in a row of gains, on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, TEIXEIRA DUARTE has a trailing twelve months EPS of €-0.03.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.08%.

More news about TEIXEIRA DUARTE.

4. MAGNORA (MGN.OL)

5.72% Price Change

Magnora ASA operates as a renewable energy development company in Norway, Sweden, and the United States. The company primarily focuses on developing wind, solar photovoltaic (PV), and battery storage projects. It also hold license agreements with the Dana Western Isles and Shell Penguins. It serves renewable energy operators, investment and oil companies, and global marine contractors. The company was formerly known as Sevan Marine ASA and changed its name to Magnora ASA in October 2018. Magnora ASA was incorporated in 2001 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with MAGNORA jumping 5.72% to €30.40 on Tuesday while Oslo Børs Benchmark Index_GI slid 0.15% to €1,425.29.

Earnings Per Share

As for profitability, MAGNORA has a trailing twelve months EPS of kr2.86.

PE Ratio

MAGNORA has a trailing twelve months price to earnings ratio of 10.63. Meaning, the purchaser of the share is investing kr10.63 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.99%.

Moving Average

MAGNORA’s worth is below its 50-day moving average of kr30.42 and below its 200-day moving average of kr30.87.

Revenue Growth

Year-on-year quarterly revenue growth grew by 36.9%, now sitting on 28.7M for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is a negative 67.3% and positive 1184% for the next.

More news about MAGNORA.

5. HOFSETH BIOCARE (HBC.OL)

4.83% Price Change

Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. The company's products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for VMS, metabolism, and active nutrition needs; CalGo, an absorbable complex mineral for bone and joint health; CollaGo; and PetGo, a non-soluble protein. The company was incorporated in 2000 and is headquartered in Ålesund, Norway.

Oslo Børs Benchmark Index_GI ended the session with HOFSETH BIOCARE jumping 4.83% to €2.17 on Tuesday while Oslo Børs Benchmark Index_GI slid 0.15% to €1,425.29.

Earnings Per Share

As for profitability, HOFSETH BIOCARE has a trailing twelve months EPS of kr-0.24.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -72.94%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 17%, now sitting on 226.1M for the twelve trailing months.

Volume

Today’s last reported volume for HOFSETH BIOCARE is 107725 which is 67.61% above its average volume of 64268.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HOFSETH BIOCARE’s stock is considered to be oversold (<=20).

Volatility

HOFSETH BIOCARE’s last week, last month’s, and last quarter’s current intraday variation average was 0.25%, 0.16%, and 1.79%.

HOFSETH BIOCARE’s highest amplitude of average volatility was 1.49% (last week), 1.15% (last month), and 1.79% (last quarter).

More news about HOFSETH BIOCARE.

6. JINHUI SHIPP TRANS (JIN.OL)

4.69% Price Change

Jinhui Shipping and Transportation Limited, an investment holding company, engages in ship chartering and owning activities internationally. The company engages in money lending; property investment activities; and management and shipping agent services. It also owns a fleet of twenty three grabs fitted supramaxes and one chartered-in-panamax with carrying capacity of approximately 1,415,930 metric tons. The company was founded in 1987 and is based in Hong Kong, Hong Kong. Jinhui Shipping and Transportation Limited operates as a subsidiary of Jinhui Holdings Company Limited.

Oslo Børs Benchmark Index_GI ended the session with JINHUI SHIPP TRANS rising 4.69% to €6.70 on Tuesday while Oslo Børs Benchmark Index_GI fell 0.15% to €1,425.29.

Earnings Per Share

As for profitability, JINHUI SHIPP TRANS has a trailing twelve months EPS of kr-3.91.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.64%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on May 25, 2023, the estimated forward annual dividend rate is 0.84 and the estimated forward annual dividend yield is 12.92%.

Volume

Today’s last reported volume for JINHUI SHIPP TRANS is 1880 which is 96.29% below its average volume of 50795.

Volatility

JINHUI SHIPP TRANS’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.32%, a negative 0.21%, and a positive 2.33%.

JINHUI SHIPP TRANS’s highest amplitude of average volatility was 1.42% (last week), 1.63% (last month), and 2.33% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 93.3%, now sitting on 95.33M for the twelve trailing months.

More news about JINHUI SHIPP TRANS.

7. NAPATECH (NAPA.OL)

3.29% Price Change

Napatech A/S offers reconfigurable computing solutions for the networking and cybersecurity applications worldwide. The company provides Link Capture Software that enables packet capture with nanosecond timestamping and replay with precise inter-frame gap control; Link Inline Software, which offers a processing architecture that offloads and accelerates flow aware application data planes; Link Virtualization Software that offloads and accelerates the Open vSwitch data plane to enhance CPU efficiency and network performance; and Link Programmable, which enables end users and OEMs to deploy FPGA computation solutions. It offers solutions for telecom operators, cloud and data center service providers, and infrastructure and defense, as well as financial services, cyber security, network management, and virtualization. Napatech A/S was incorporated in 2003 and is based in Copenhagen, Denmark.

Oslo Børs Benchmark Index_GI ended the session with NAPATECH jumping 3.29% to €34.50 on Tuesday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI fell 0.15% to €1,425.29, after three consecutive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, NAPATECH has a trailing twelve months EPS of kr-0.71.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -56.66%.

More news about NAPATECH.

8. NRC GROUP (NRC.OL)

2.93% Price Change

NRC Group ASA, together with its subsidiaries, operates as a rail infrastructure company in Norway, Sweden, and Finland. It offers groundwork services, including excavations, transport, masses sorting, and ditching, as well as water and drainage systems; and signaling systems, digital telecom systems, electro, tracks, and station buildings and terminals, as well as catenary systems comprising wires, masts, switches, and return current systems. The company also provides complementary services, such as concrete work, recycling, demolition, and mass transport services; and specialized trackwork services. In addition, it offers railway construction and maintenance, civil construction, and environmental services; related infrastructure services, including bridges and crossings; and electrical installations for rail, light rail, and metro systems. The company was formerly known as Blom ASA and changed its name to NRC Group ASA in May 2015. NRC Group ASA was founded in 1966 and is headquartered in Lysaker, Norway.

Oslo Børs Benchmark Index_GI ended the session with NRC GROUP rising 2.93% to €10.55 on Tuesday, after four consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI fell 0.15% to €1,425.29, after three sequential sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, NRC GROUP has a trailing twelve months EPS of kr-0.17.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.5%.

More news about NRC GROUP.

9. VALUE8 CUM PREF (PREVA.AS)

2.88% Price Change

Value8 N.V. is a private equity firm specializing in middle market, buyout, add-on and growth capital investments in small and medium-sized companies. The firm primarily invests in the food, healthcare, business and financial services, energy, safety and security, water and environment, leisure, luxury products and internet sectors. It typically invests in Western Europe, primarily in the Netherlands, Belgium and France. The firm considers investments in companies with an enterprise value between €10 million ($10.74 million) and €150 million ($208.87 million). The firm prefers to take a seat on the board of directors and seeks to exit the investment through a public listing. Value8 NV was founded in 2008 and is headquartered in Bussum, Netherlands.

AEX-Index ended the session with VALUE8 CUM PREF jumping 2.88% to €4.81 on Tuesday, after four successive sessions in a row of losses. AEX-Index dropped 0.43% to €933.47, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, VALUE8 CUM PREF has a trailing twelve months EPS of €1.869.

PE Ratio

VALUE8 CUM PREF has a trailing twelve months price to earnings ratio of 2.57. Meaning, the purchaser of the share is investing €2.57 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.

More news about VALUE8 CUM PREF.

10. BELSHIPS (BELCO.OL)

2.87% Price Change

Belships ASA owns and operates dry bulk ships worldwide. It operates through Belships and Lighthouse Navigation segments. The company operates a fleet of 38 modern Supra/Ultramax bulk carriers, including newbuildings. It also provides technical, crewing, port agency, and logistical services. The company was founded in 1918 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with BELSHIPS jumping 2.87% to €23.30 on Tuesday while Oslo Børs Benchmark Index_GI fell 0.15% to €1,425.29.

Earnings Per Share

As for profitability, BELSHIPS has a trailing twelve months EPS of kr2.41.

PE Ratio

BELSHIPS has a trailing twelve months price to earnings ratio of 9.67. Meaning, the purchaser of the share is investing kr9.67 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 50.41%.

Sales Growth

BELSHIPS’s sales growth for the next quarter is negative 23.6%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 42.5% and a negative 64.2%, respectively.

Volume

Today’s last reported volume for BELSHIPS is 95728 which is 74.21% below its average volume of 371238.

More news about BELSHIPS.

Losers Today

1. ATOS (ATO.PA)

-10.8% Price Change

Atos SE provides digital transformation solutions and services worldwide. It offers advanced computing solutions; analytics, artificial intelligence, and automation solutions; cloud solutions; customer journey analytics and digital customer experience; decarbonization solutions; digital consulting; digital workplace solutions; edge computing and Internet of things solutions; and modern applications and platforms. The company also provides advance detection and response, data protection and governance, digital workplace security, IoT and OT security, trusted digital identities, and cybersecurity solutions; and infrastructure and foundation services. It serves financial services and insurance, healthcare and life sciences, manufacturing, public sector and defense, resources and services, and telecommunication and media industries. The company was incorporated in 1982 and is headquartered in Bezons, France.

CAC 40 ended the session with ATOS sliding 10.8% to €1.14 on Tuesday, after four successive sessions in a row of gains. CAC 40 fell 0.69% to €7,580.03, after three consecutive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, ATOS has a trailing twelve months EPS of €-31.04.

More news about ATOS.

2. BENEVOLENTAI (BAI.AS)

-10.56% Price Change

BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

AEX-Index ended the session with BENEVOLENTAI falling 10.56% to €0.61 on Tuesday, following the last session’s upward trend. AEX-Index fell 0.43% to €933.47, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-0.64.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.01%.

More news about BENEVOLENTAI.

3. PHOTOCURE (PHO.OL)

-9.22% Price Change

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PHOTOCURE sliding 9.22% to €53.20 on Tuesday, after two consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI slid 0.15% to €1,425.29, after three sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, PHOTOCURE has a trailing twelve months EPS of kr0.18.

PE Ratio

PHOTOCURE has a trailing twelve months price to earnings ratio of 295.56. Meaning, the purchaser of the share is investing kr295.56 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.03%.

Moving Average

PHOTOCURE’s worth is way under its 50-day moving average of kr60.86 and way below its 200-day moving average of kr59.14.

Yearly Top and Bottom Value

PHOTOCURE’s stock is valued at kr53.20 at 22:40 EST, way under its 52-week high of kr71.90 and way above its 52-week low of kr40.70.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is 231.2% and a drop 16.7% for the next.

More news about PHOTOCURE.

4. MOTORK (MTRK.AS)

-7.72% Price Change

MotorK plc, together with its subsidiaries, provides software-as-a-service for the automotive retail industry in Italy, Spain, France, Germany, and the Benelux Union. The company offers a combination of automotive SaaS products and digital solutions to the digital lead generation, management, and nurturing process; and technology and software solutions for car manufacturers, dealers, and service centers. The company also provides WebSparK, a web platform for traffic acquisition and lead generation performance; LeadSparK, a CRM platform to support the activities of car dealerships and automotive manufacturers; and StockSparK, an automotive stock management platform. MotorK plc was incorporated in 2010 and is based in Milan, Italy.

AEX-Index ended the session with MOTORK falling 7.72% to €5.50 on Tuesday while AEX-Index fell 0.43% to €933.47.

Earnings Per Share

As for profitability, MOTORK has a trailing twelve months EPS of €-0.33.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.36%.

More news about MOTORK.

5. ALFEN (ALFEN.AS)

-5.41% Price Change

Alfen N.V., through its subsidiaries, engages in the design, engineering, development, production, and service of smart grids, energy storage systems, and electric vehicle charging equipment. The company offers smart grid solutions, including secondary transformer substations for grid operators, devices for grid automation, and proprietary back-end systems for remote management and control of electricity grids, as well as micro-grids; and supplementary offerings to grid connect amongst others PV farms, electric vehicle (EV) fast-charging hubs, and industrial companies. It also provides energy storage systems comprising stationary and mobile battery energy storage solutions for load balancing, peak shaving, grid frequency control, and energy trading solutions, as well as embedded software and back-office solutions that enables remote monitoring, control, and support for storage applications. In addition, the company offers smart and connected electric vehicle chargers for use at the home, retail, workplace, and public locations, as well as an online management platform for charging infrastructure and standardized solutions for smart charging, load balancing, charging hubs, and plug and charge functionalities. It operates primarily in the Netherlands, Austria, Belgium, Finland, France, Germany, Italy, Norway, Poland, Spain, Sweden, Switzerland, the United Kingdom, and the rest of Europe. The company was founded in 1937 and is headquartered in Almere, the Netherlands.

AEX-Index ended the session with ALFEN sliding 5.41% to €17.48 on Tuesday, after two sequential sessions in a row of losses. AEX-Index fell 0.43% to €933.47, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, ALFEN has a trailing twelve months EPS of €1.36.

PE Ratio

ALFEN has a trailing twelve months price to earnings ratio of 12.85. Meaning, the purchaser of the share is investing €12.85 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.98%.

Volatility

ALFEN’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.14%, a negative 4.01%, and a positive 4.34%.

ALFEN’s highest amplitude of average volatility was 2.17% (last week), 6.61% (last month), and 4.34% (last quarter).

Sales Growth

ALFEN’s sales growth for the current quarter is 50.5%.

More news about ALFEN.

6. ATLANTIC SAPPHIRE (ASA.OL)

-5.12% Price Change

Atlantic Sapphire ASA, together with its subsidiaries, engages in the production and sale of land-based salmon in Denmark and the United States. The company was incorporated in 2010 and is headquartered in Vikebukt, Norway.

Oslo Børs Benchmark Index_GI ended the session with ATLANTIC SAPPHIRE sliding 5.12% to €5.30 on Tuesday while Oslo Børs Benchmark Index_GI dropped 0.15% to €1,425.29.

Earnings Per Share

As for profitability, ATLANTIC SAPPHIRE has a trailing twelve months EPS of kr-37.54.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 55.3%, now sitting on 18.95M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ATLANTIC SAPPHIRE’s stock is considered to be overbought (>=80).

More news about ATLANTIC SAPPHIRE.

7. GLINTT (GLINT.LS)

-5.1% Price Change

Glintt – Global Intelligent Technologies, S.A. provides IT consulting services for banking, insurance, public administration, and utilities sectors in Portugal, Spain, and Angola. It operates through two segments: Health and Other Markets. The company engages in the sale of equipment, furniture, consumables, and robotics solutions; development of architectural projects; and design and conception of lay-out and image for pharmacies, training, equipment maintenance, and consultancy projects. It licenses proprietary software solutions for healthcare providers, such as clinics, hospitals, pharmacies, and other bodies of the ministry of health; and develops, implements, and maintains software services for the health sector. In addition, the company implements ERPs, integrates internet systems, and develops tailor-made applications services. Further, the company develops, implements, and integrates partner platforms with emphasis on the BPM, ERP, BI and mobility solutions; and integrates IT infrastructures, as well as support for networking, security, storage systems, and database management. Glintt – Global Intelligent Technologies, S.A. was incorporated in 1995 and is based in Sintra, Portugal. Glintt – Global Intelligent Technologies, S.A. operates as a subsidiary of Farminveste – Investimentos, Participações E Gestão S.A.

PSI ended the session with GLINTT falling 5.1% to €0.48 on Tuesday, after two sequential sessions in a row of gains. PSI rose 1.04% to €6,775.93, after three sequential sessions in a row of gains, on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, GLINTT has a trailing twelve months EPS of €0.05.

PE Ratio

GLINTT has a trailing twelve months price to earnings ratio of 9.68. Meaning, the purchaser of the share is investing €9.68 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.11%.

More news about GLINTT.

8. CELYAD ONCOLOGY (CYAD.BR)

-4.94% Price Change

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with CELYAD ONCOLOGY falling 4.94% to €0.26 on Tuesday while BEL 20 slid 0.01% to €4,006.47.

Earnings Per Share

As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.36.

Volume

Today’s last reported volume for CELYAD ONCOLOGY is 10553 which is 28.13% below its average volume of 14685.

Volatility

CELYAD ONCOLOGY’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.59%, a negative 0.65%, and a positive 3.14%.

CELYAD ONCOLOGY’s highest amplitude of average volatility was 3.27% (last week), 4.38% (last month), and 3.14% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CELYAD ONCOLOGY’s stock is considered to be oversold (<=20).

More news about CELYAD ONCOLOGY.

9. COFINA,SGPS (CFN.LS)

-4.88% Price Change

Cofina, SGPS, S.A., through its subsidiaries, engages in the publication of newspapers and magazines in Portugal. The company offers newspapers, including Correio da Manha, a daily newspaper; Record, a daily sport newspaper; Negocios, an economic newspaper; and Destak, a free newspaper. It also provides Sábado, an entertainment weekly magazine; TV Guia, weekly television magazine; Máxima, an online publication that develops topics related to culture, fashion, beauty, health and well-being, and travel and lifestyle; Flash, an online publication which addresses the social current affairs of national and international public figures; and Correio da Manhã TV (cmTV), a cable platform. In addition, the company engages in the investment management activities. The company was incorporated in 1990 and is headquartered in Porto, Portugal.

PSI ended the session with COFINA,SGPS falling 4.88% to €0.82 on Tuesday while PSI jumped 1.04% to €6,775.93.

Earnings Per Share

As for profitability, COFINA,SGPS has a trailing twelve months EPS of €-1.4.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Yearly Top and Bottom Value

COFINA,SGPS’s stock is valued at €0.82 at 22:40 EST, way above its 52-week high of €0.50.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on May 17, 2023, the estimated forward annual dividend rate is 0.03 and the estimated forward annual dividend yield is 6.48%.

Volatility

COFINA,SGPS’s last week, last month’s, and last quarter’s current intraday variation average was 27.64%, 5.96%, and 3.26%.

COFINA,SGPS’s highest amplitude of average volatility was 27.64% (last week), 7.22% (last month), and 3.26% (last quarter).

More news about COFINA,SGPS.

10. SEQUANA MEDICAL (SEQUA.BR)

-4.35% Price Change

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Ghent, Belgium.

BEL 20 ended the session with SEQUANA MEDICAL sliding 4.35% to €1.21 on Tuesday, after two consecutive sessions in a row of losses. BEL 20 fell 0.01% to €4,006.47, after four successive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.22.

Volatility

SEQUANA MEDICAL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.82%, a negative 1.06%, and a positive 2.61%.

SEQUANA MEDICAL’s highest amplitude of average volatility was 3.54% (last week), 2.19% (last month), and 2.61% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 28.4%, now sitting on 712.17k for the twelve trailing months.

Volume

Today’s last reported volume for SEQUANA MEDICAL is 30122 which is 15.1% below its average volume of 35481.

More news about SEQUANA MEDICAL.

Stay up to date with our winners and losers daily report